EPA:DIM Sartorius Stedim Biotech (DIM) Stock Price, News & Analysis €203.90 +3.50 (+1.75%) As of 01/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlines About Sartorius Stedim Biotech Stock (EPA:DIM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DIM alerts:Sign Up Key Stats Today's Range€199.80▼€205.3050-Day Range€167.30▼€203.8052-Week Range N/AVolume47,923 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.Read More… Receive DIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address DIM Stock News HeadlinesBernstein Sticks to Their Hold Rating for Sartorius Stedim Biotech (0RG8)January 16, 2025 | markets.businessinsider.comSartorius Stock: JPMorgan Boost Drives 4% Market SurgeJanuary 7, 2025 | finanznachrichten.deStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.January 22, 2025 | Banyan Hill Publishing (Ad)RBC Capital Sticks to Its Hold Rating for Sartorius (0NIR)December 9, 2024 | markets.businessinsider.comJefferies Keeps Their Hold Rating on Sartorius (0NIR)November 20, 2024 | markets.businessinsider.comFrance shares lower at close of trade; CAC 40 down 2.69%November 14, 2024 | msn.comFrance stocks lower at close of trade; CAC 40 down 2.69%November 14, 2024 | msn.comFrance shares higher at close of trade; CAC 40 up 0.80%November 2, 2024 | msn.comSee More Headlines DIM Stock Analysis - Frequently Asked Questions How have DIM shares performed this year? Sartorius Stedim Biotech's stock was trading at €188.70 at the start of the year. Since then, DIM shares have increased by 6.2% and is now trading at €200.40. View the best growth stocks for 2025 here. What other stocks do shareholders of Sartorius Stedim Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sartorius Stedim Biotech investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Corbus Pharmaceuticals (CRBP), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX) and C3.ai (AI). Industry, Sector and Symbol Stock ExchangeEPA SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolEPA:DIM CUSIPN/A CIKN/A Webwww.sartorius.com Phone33 4 42 84 56 00FaxN/AEmployees10,493Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (EPA:DIM) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sartorius Stedim Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.